CORRECTED-MNI: Fed's Hammack-Near Or At Time To Slow Rate Cuts

MNI BRIEF: Fed's Goolsbee Sees Rates Fair Bit Lower In A Year

CANADA JOBLESS RATE +6.8% VS FORECAST +6.6%, PRIOR +6.5%

MNI China Daily Summary: Friday, December 6

MNI: PBOC Net Drains CNY288.1 Bln via OMO Friday

MNI: PBOC Sets Yuan Parity Lower At 7.1848 Fri; -1.64% Y/Y

MNI: UNIV OF MICHIGAN CONSUMER SENTIMENT PRELIMINARY DEC INDEX 74.0

CANADA NOV IVEY PURCHASING MANAGERS INDEX 52.3 SA

EZ/UK Bond Supply Calendar: Austria, UK Auction on Tuesday

MNI EXCLUSIVE: EU-Mercosur Deal Close, But Likely Short-Lived - Officials

AUSTRALIA: 2025 Election Outcome Looking More Uncertain According To Newspoll

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Roche (ROSW: Aa2/AA): Dropping On Weight-Loss Pill Fail

HEALTHCARE
BulletCredit Bullets
  • Neutral for credit: This is really an equity story for now
  • Roche is clearly desperate to show some progress in the gold-rush of weight-loss medication.
  • It released the results of a small Phase 1 trial for CT-996.
  • While the pill (not injection) was effective it had negative side effects including raised liver enzymes.
  • The equity market is focussing on the negatives.
  • Yesterday, NOVOB rallied on results for its early-stage pill trials.
  • Pills are preferable to injections but the dosage has to be higher and therefore more prone to side-effects.
83 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Neutral for credit: This is really an equity story for now
  • Roche is clearly desperate to show some progress in the gold-rush of weight-loss medication.
  • It released the results of a small Phase 1 trial for CT-996.
  • While the pill (not injection) was effective it had negative side effects including raised liver enzymes.
  • The equity market is focussing on the negatives.
  • Yesterday, NOVOB rallied on results for its early-stage pill trials.
  • Pills are preferable to injections but the dosage has to be higher and therefore more prone to side-effects.